[태그:] 영문
-

3billion Launches Family Insight Test, a Family-Based Precision Genomic Testing Service
● Premium WES/WGS Testing for High-Risk Families Facing Infertility, Recurrent Pregnancy Loss, or Inherited Disease Risk ● Expands AI Variant Interpretation Technology to Family-Level Genetic Risk Analysis ● Pilot Testing in Middle East & Africa Confirmed high Demand; leading to service Expansion to Asia and South America 3billion (CEO: Changwon Keum), an AI-powered rare disease…
-

70 Patients Found New Answers Through Reanalysis of Genetic Testing: March 2026
Is a single genetic test result the end of the diagnostic journey?At 3billion, we believe diagnosis is an ongoing process. That’s why we focus not only on the test itself, but on what comes after:Reanalysis. For all cases previously reported as Inconclusive or Negative,3billion performs automated reanalysis through a continuous system.Each month, dozens of reports…
-

Cleidocranial Dysplasia: Why Genetic Testing Matters and When to Consider It
📍 Key Takeaways 1. What is CCD: Core Clinical Phenotypes Cleidocranial Dysplasia (CCD) is an autosomal dominant rare skeletal dysplasia caused by RUNX2 gene variants, with a reported birth prevalence of approximately 1/1,000,000.[1] A systematic review of 283 CCD patients found dental anomalies — including supernumerary teeth and permanent tooth eruption failure — in over…
-

What’s New in CHARGE Syndrome Research: A 2024–2026 Update
📍Key Takeaways A Well-Characterized Syndrome With Much Still to Learn CHARGE syndrome is a rare, complex congenital disorder most commonly caused by pathogenic variants in the CHD7 gene. The acronym reflects its cardinal features: Coloboma, Heart defect, Atresia of the choanae, Retardation of growth, Genital hypoplasia, and Ear anomaly/deafness. CHD7 was identified as the causative…
-

Genetic Variants Determine Prognosis: Genotype–Phenotype Correlations in Congenital and Infantile Nephrotic Syndrome
📍 Key Takeaways • More than 50% of CNS and infantile NS cases have a monogenic cause; four genes — NPHS1, NPHS2, WT1, and LAMB2 — account for two-thirds of all cases. • Even within the same gene, earlier onset (CNS) is associated with a more severe genotype and faster progression to renal failure. •…
-

Key Diagnostic Outcomes from Mexico in 2025
In 2025, 825 patients received rare disease diagnoses through 3billion in Mexico. Rare disease patients wait an average of 4 to 6 years(Fatoumata Faye, 2024) before receiving an accurate diagnosis. Most spend years cycling through dozens of hospitals and undergoing countless repeated tests, only to be told the cause remains unknown. Mexico is no exception…
-

ACMG 2026: 3billion Takes GEBRA to the Global Stage
The American College of Medical Genetics and Genomics (ACMG) is the leading authority in medical genetics and genomics — a professional academic organization spanning clinical research, education, and policy advocacy. At its core, ACMG is dedicated to integrating genetics and genomics across modern medicine, publishing essential guidelines for the medical genetics community including laboratory technical…
-

Genetic Checkpoints After Down Syndrome Diagnosis: What Clinicians Should Not Miss
Karyotype testing remains the gold-standard first-line diagnostic tool for confirming Down syndrome (DS). It reliably identifies Trisomy 21 and detects Robertsonian translocations, and in the majority of patients presenting with a typical phenotype, karyotyping alone is sufficient. That said, karyotyping has well-recognized structural limitations. Low-level mosaicism may go undetected with standard G-banding. Submicroscopic copy number…
-

3billion Showcases AI-Powered Variant Interpretation Innovation at ACMG 2026
BALTIMORE, MD – March 10, 2026 – 3billion (CEO Changwon Keum), a leader in AI-powered rare disease diagnostics, today announced its participation in the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, taking place March 10 -14 in Baltimore, Maryland. The ACMG Annual Meeting is the world’s premier conference in…
-

Redefining Genetic Disease ‘Carriers’: Beyond Simple Transmitters to Real Health Impacts
📍Summary: Carriers of genetic diseases are not merely asymptomatic gene transmitters — depending on genetic and environmental factors, they can experience actual health symptoms, making personalized healthcare tailored to carriers a necessity. A recent article (February 15, 2026) challenged the conventional wisdom that carriers are ‘asymptomatic,’ drawing on specific diseases and carrier cases. Starting from…